View details of this raise on Seedstage

Scottsdale, AZ

Developing solutions for healthspan optimization through biotechnology.

• Biotechnology Focus: Zephyr Group develops solutions at the intersection of therapeutic peptides, phytoceuticals, and advanced delivery systems.
• Platform-First Strategy: The company ensures products are synergistic, highly bioavailable, and validated through clinical data.
• Metabolic Health Assets: Zephyr is positioned with high-demand assets targeting metabolic health and GLP-1 awareness.
• Strategic Use of Proceeds: Funds will support regulatory compliance, commercialization, and potential strategic acquisitions.
• Founded on Prevention: Zephyr Group was established with a focus on prevention as a sustainable path in healthcare.

Zephyr Group is an emerging biotechnology company dedicated to optimizing healthspan by developing evidence-based solutions that bridge the gap between nature and modern bioscience. The company is moving beyond the reactive healthcare model to address the root causes of aging and metabolic decline. Zephyr Group’s platform-first strategy focuses on therapeutic peptides, high-potency phytoceuticals, and advanced delivery systems to create products that are synergistic, highly bioavailable, and validated through rigorous clinical data and quality control.

The current fundraising aims to support Zephyr Group’s growth and expansion. At the minimum target, proceeds will be used for regulatory compliance, investor relations, and foundational marketing. If the maximum target is reached, the funds will accelerate commercialization of GLP-1 and metabolic assets, prepare for a larger institutional-grade raise, and evaluate strategic acquisitions to expand the company’s intellectual property portfolio. Founded in 2021, Zephyr Group is committed to building a standard for the longevity industry through a focus on integrity and accountability.

Company Info

Zephyr Group develops biotechnology solutions for healthspan optimization, focusing on metabolic health and advanced delivery systems.

Zephyr Group is a biotechnology company focused on optimizing healthspan by developing solutions that integrate therapeutic peptides, high-potency phytoceuticals, and advanced delivery systems. The company aims to move beyond traditional reactive healthcare models by addressing the root causes of aging and metabolic decline. Zephyr’s platform-first strategy ensures that its products are synergistic, highly bioavailable, and validated through rigorous clinical data and quality control.

Zephyr Group’s product pipeline targets the growing demand for metabolic health solutions, including assets for Type II diabetes and weight management. The company leverages liposomal and exosomal delivery systems to enhance the bioavailability of its compounds. Founded in 2021, Zephyr is committed to building a standard for the longevity industry, focusing on prevention as a sustainable path to health. The company is strategically positioned to capitalize on the global shift towards personalized wellness and science-backed wellness innovations.